File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study

TitleEditorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study
Authors
Mak, Lung‐YiFung, James
Issue Date10-Aug-2023
PublisherWiley
Citation
Alimentary Pharmacology and Therapeutics, 2023, v. 58, n. 5, p. 548-549 How to Cite?
DOI: http://dx.doi.org/10.1111/apt.17630
Persistent Identifierhttp://hdl.handle.net/10722/337985
ISSN
0269-2813
2023 Impact Factor: 6.6
2023 SCImago Journal Rankings: 2.794
ISI Accession Number ID
WOS:001146882800007

 

DC FieldValueLanguage
dc.contributor.authorMak, Lung‐Yi-
dc.contributor.authorFung, James-
dc.date.accessioned2024-03-11T10:25:25Z-
dc.date.available2024-03-11T10:25:25Z-
dc.date.issued2023-08-10-
dc.identifier.citationAlimentary Pharmacology and Therapeutics, 2023, v. 58, n. 5, p. 548-549-
dc.identifier.issn0269-2813-
dc.identifier.urihttp://hdl.handle.net/10722/337985-
dc.languageeng-
dc.publisherWiley-
dc.relation.ispartofAlimentary Pharmacology and Therapeutics-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleEditorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study-
dc.typeArticle-
dc.identifier.doi10.1111/apt.17630-
dc.identifier.scopuseid_2-s2.0-85167426589-
dc.identifier.volume58-
dc.identifier.issue5-
dc.identifier.spage548-
dc.identifier.epage549-
dc.identifier.eissn1365-2036-
dc.identifier.isiWOS:001146882800007-
dc.identifier.issnl0269-2813-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats